This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Claire Leurent
Principal, Venture Investments at Johnson & Johnson Development Corp, JJDC

Profile

Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA.  Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. 

Prior to joining JJDC, Claire was Investment Director, then Managing Director, at Samsung Ventures with a focus on Life Science, Health Economics and Connected Health sectors.  Prior to Samsung Ventures, she spent 14 years in the pharmaceutical industry in R&D. At Pfizer, she led teams in design and implementation of clinical plans from First in Human to Proof of Concept studies with end-to-end accountability for various development programs ranging from small molecules and biologics to digital technologies. Prior to Pfizer, Claire supported large global multicentric phase 3 pre/registration studies and launch activities at Wyeth Pharmaceuticals in Neuroscience and Women Health. Prior to Wyeth, she was Project Manager at Forenap, a neuroscience CRO, where she advanced a portfolio of clinical protocols for diverse global pharma clients. In this position, she acquired first-hand operational experience in clinical trials and oversaw First in Human studies at the Phase 1 center.

Agenda Sessions

  • Startup Springboard

    3:00pm